Want to see CTEV full AI Analyst Report?
CTEV Stock Chart & Stats
$39.39
$0.21(0.97%)
At close: 4:00 PM EDT
$39.39
$0.21(0.97%)
Day’s Range― - ―
52-Week Range$11.50 - $73.68
Previous Close$21.82
Volume81.92K
Average Volume (3M)130.96K
Market Cap
$366.74M
Enterprise Value$5.25K
Total Cash (Recent Filing)$14.37M
Total Debt (Recent Filing)$4.62B
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Nov 10, 2026EPS Estimate
-3.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.01
Shares Outstanding16,947,462
10 Day Avg. Volume173,399
30 Day Avg. Volume130,961
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.04
Price to Sales (P/S)0.73
P/FCF Ratio-57.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$45.83Price Target Upside16.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-15.12
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Improving Revenue And EBITDA PerformanceSustained quarterly growth and exceptionally strong adjusted EBITDA margins indicate improving operating execution and meaningful earnings capacity. The fifth consecutive quarter of year-over-year revenue growth, combined with scale economics, supports continued investment in products, technology, and customer expansion over the next several quarters.
Strong Bookings Momentum And Expanding PipelineRapid ACV growth, larger deal sizes, and a well-covered pipeline strengthen forward revenue visibility and suggest increasing customer traction. Although bookings convert over several quarters, this sales momentum can support durable growth as new contracts begin contributing revenue and expand the company’s recurring opportunity base.
AI Capabilities And Technology ModernizationInvestment in cloud infrastructure, data architecture, and deployed AI models can improve Claritev’s healthcare analytics and payment-integrity offerings. These capabilities may deepen customer value, expand automation, and reinforce differentiation as payers and other healthcare organizations seek measurable savings from increasingly data-intensive workflows.
Bears Say
High Leverage And Negative EquityHeavy leverage and negative equity materially reduce financial flexibility and leave the company less able to absorb operating shocks. Debt-related obligations can constrain capital allocation, increase refinancing sensitivity, and make it harder to fund growth initiatives internally even if operating performance continues to improve.
Net Losses And Volatile ProfitabilityThe large bottom-line loss shows that strong operating metrics have not yet translated into sustainable net profitability. Continued earnings volatility can limit internally generated capital, weaken resilience during periods of slower growth, and increase reliance on operating improvements or financing to support the business.
Regulatory Complexity And Revenue Timing RiskChanging NSA and IDR requirements add operational and compliance complexity to Claritev’s healthcare services model. Implementation may delay volume impacts and require execution investment, while related timing uncertainty can make revenue less predictable and complicate planning even if the long-term regulatory environment creates opportunities.
Claritev News
CTEV FAQ
What was Claritev’s price range in the past 12 months?
Claritev lowest stock price was $11.50 and its highest was $73.68 in the past 12 months.
What is Claritev’s market cap?
Claritev’s market cap is $366.74M.
When is Claritev’s upcoming earnings report date?
Claritev’s upcoming earnings report date is Nov 10, 2026 which is in 39 days.
How were Claritev’s earnings last quarter?
Claritev released its earnings results on Aug 07, 2026. The company reported -$3.49 earnings per share for the quarter, beating the consensus estimate of -$4.121 by $0.631.
Is Claritev overvalued?
According to Wall Street analysts Claritev’s price is currently Undervalued.
Does Claritev pay dividends?
Claritev does not currently pay dividends.
What is Claritev’s EPS estimate?
Claritev’s EPS estimate is -3.63.
How many shares outstanding does Claritev have?
Claritev has 16,947,462 shares outstanding.
What happened to Claritev’s price movement after its last earnings report?
Claritev reported an EPS of -$3.49 in its last earnings report, beating expectations of -$4.121. Following the earnings report the stock price went up 21.423%.
Which hedge fund is a major shareholder of Claritev?
Currently, no hedge funds are holding shares in CTEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Claritev Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.83 (16.36% Upside)
$45.83 (16.36% Upside)
Blogger Sentiment
Neutral
CTEV Sentiment 67%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 180.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $393.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Claritev
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
CTEV Company Deck
CTEV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: multi-quarter revenue growth, record/near-record EBITDA and cash flow, significant bookings acceleration and a substantially enlarged pipeline. Management raised revenue and EBITDA guidance and highlighted successful execution across TPA, Claims Intelligence and AI-enabled initiatives. Offsetting considerations include timing and mix-driven pressure on revenue per claim, network comparables impacted by prior-year one-time items, a near-term Payments timing miss, and some volume/regulatory uncertainty that introduces short-term variability. Overall, the positive metrics and trajectory substantially outweigh the manageable timing and mix headwinds.View all CTEV earnings summariesCTEV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$45.83
▲(16.36% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
16.94% Insiders
29.87% Mutual Funds
37.00% Other Institutional Investors
9.45% Public Companies and
Individual Investors










